Technical Data
Epstein Barr Virus, Latent Membrane Protein (EBV LMP, Human Herpes virus 4, HHV4)
This pool of four monoclonal antibodies detects the latent membrane protein (LMP-1) derived from the BNLF1 gene of Epstein-Barr virus (EBV). This antibody cocktail will help detect EBV infected cells in normal and uncharacterized tissues.

Suitable for use in Immunohistochemistry. Other applications not tested.

Recommended Dilution:
Immunohistochemistry: 1:100-1:200 for 1hr at RT
Optimal dilutions to be determined by the researcher.

Positive Control:
Lymph node, Hodgkin’s disease (about 50% of cases are likely to be positive). Cytoplasmic staining pattern may be observed in Reed Sternberg cells.

Storage and Stability:
Lyophilized powder may be stored at -20°C. Stable for 12 months at -20°C. Reconstitute with sterile ddH2O. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Reconstituted product is stable for 12 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
MabIgG1CS1, CS2, CS3, CS4Supernatant
1ml-20°CBlue IceMouse
Not determined
Fusion protein including sequences of the EBV encoded latent membrane protein (LMP-1) and bacterial beta-galactosidase.
Supplied as a lyophilized powder in 15mM sodium azide. Reconstitute with 1ml dH2O.
Recognizes Epstein Barr Virus.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1.Murray P G, Young L S, Rowe M, et al.. Immunohistochemical demonstration of the Epstein-Barr virus-encoded latent membrane protein in paraffin sections of Hodgkin’s disease. Journal of Pathology. 166:1-5 (1992). 2.Herbst H, Dallenbach F, Hummel M, et al.. Epstein-Barr virus DNA and latent gene products in Ki-1 (CD30)-positive anaplastic large cell lymphoma. Blood. 78:1-10 (1991). 3.Jarrett R F, Gallagher A, Jones D B, et al.. Detection of Epstein-Barr virus genomes in Hodgkin’s disease: Relation to age. Journal of Clinical Pathology. 44:844-848 (1991). 4.Pallesen G, Hamilton-Dutoit S J, Rowe M, et al.. Expression of Epstein-Barr (EBV) latent gene products in tumor cells of Hodgkin’s disease. Lancet. 337:320-322 (1991). 5.Haribuchi Y, Yamanaka N, Katura A, et al.. Epstein-Barr virus in nasal T-cell lymphomas in patients with lethal medline granuloma. Lancet. 335:128-130 (1990). 6.Young L, Alfieri C, Hennesy K, et al.. Expression of Epstein-Barr virus transformation-associated genes in tissue of patients with EBV lymphoprolifera- tive disease. New England Journal of Medicine. 321:1080-1085 (1989).
7.Fahraeus R, Li-Fu H, Ernberg I, et al.. Expression of the Epstein-Barr virus genome in nasopharyngeal carcinoma. International Journal of Cancer. 42:329-338 (1988). 8.Rowe M, Evans H S, Young L S, et al.. Monoclonal antibodies to the latent membrane protein of Epstein-Barr virus reveal heterogeneity of the protein and inducible expression in virus-transformed cells. Journal of General Virology. 68:1575-1586 (1987).